According to multiple reports, former Yale women’s hockey player Mandi Schwartz died after a battle with leukemia. Surrounded by friends and family, the 23-year-old finally succumbed to the disease at 1:35 p.m. eastern time on Sunday after a two-year battle.
Schwartz became a media sensation initially as a forward on Yale’s women’s hockey team. She drew national attention for both her 73 games-played streak, and her continent-wide search for a bone-marrow donor.
Players and coaches often spoke of her unwavering spirit and heart. It was that same tough, dedicated attitude that allowed her two battle the horrendous disease for two years and serve as both a model and inspiration to people all over the world.
Schwartz suffered from acute myeloid leukemia, a disease that was found to have returned in April 2010. Originally, it had been in remission since May 2009, however it ultimately returned. A test conducted earlier in the month indicated that the disease was back in remission.
Yale has come out and publicly said that he marrow drives on Schwartz’s behalf as of last Spring had added over 4,200 donor registries to the United States and Canada.
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
